Interventional × Lung Diseases × pembrolizumab × Clear all
NCT07162883 2025-09-09

Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC)

Qilu Pharmaceutical Co., Ltd.

Phase 3 Not yet recruiting
122 enrolled
NCT02909452 2022-01-25

Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors

Syndax Pharmaceuticals

Phase 1 Completed
30 enrolled